Osteogenesis imperfecta type 3
MONDO:0009804Osteogenesis imperfecta type III is a severe type of osteogenesis imperfecta (OI), a genetic disorder characterized by increased bone fragility, low bone mass and susceptibility to bone fractures. The main signs of type III include very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta (DI).
Also known as: OI type 3, OI3, osteogenesis imperfecta type 3, osteogenesis imperfecta type III, progressive deforming osteogenesis imperfecta, severe osteogenesis imperfecta, OI type III, OI, type 3
9 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug aims to strengthen bones in kids with rare brittle bone disease
Disease control OngoingThis phase 3 study tests setrusumab, a monthly IV infusion, in 6 Japanese children with osteogenesis imperfecta (types I, III, or IV), a condition that causes fragile bones and frequent fractures. The main goal is to see if the drug lowers the number of fractures, including spine…
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to slash fractures in brittle bone disease
Disease control OngoingThis study tests a medicine called setrusumab in people with osteogenesis imperfecta (brittle bone disease). The goal is to see if it can lower the number of bone fractures. About 183 participants with types I, III, or IV of the disease who have had recent fractures will receive …
Phase: PHASE2, PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to cut fractures in kids with brittle bones
Disease control OngoingThis study tests a new medicine called setrusumab against standard bone-strengthening drugs (bisphosphonates) in children aged 2 to under 7 with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. The goal is to see if setrusumab can lower the number of bone break…
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Fetal stem cells aim to mend broken bones in infants
Disease control OngoingThis early-phase trial tests whether fetal stem cells given before or after birth can safely help infants with severe osteogenesis imperfecta, a genetic condition causing fragile bones and frequent fractures. Up to 18 children will receive multiple doses of the cells. The main go…
Phase: PHASE1, PHASE2 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC